Media kit

For press and media inquiries, please contact media@​egenesis.​com.

eGenesis is a clinical-stage biotechnology company developing human-compatible engineered organs for transplant to address the global organ shortage and revolutionize the treatment of organ failure. The Company’s genome engineering platform enables the production of transgenic donors carrying edits that address safety and efficacy for patients.

EGEN-2784, a genetically engineered porcine kidney, is the Company’s lead program for patients with kidney failure. The product was used in the first-ever kidney xenotransplant and is currently being evaluated in the clinic. The product carries three classes of genetic modifications designed to improve compatibility and support long-term function in human recipients.

The company is pursuing additional programs for liver failure as well as heart failure. eGenesis is headquartered in Cambridge, MA.